VYRA™ Product Line Update

Halifax, Nova Scotia, 20 May, 2022 – Today, MedMira Inc. (MedMira) (TSXV: MIR) provides an update on the Company’s regulatory work for Canada for its VYRA™ product line. On the 10th of May 2022, Health Canada issued to all stakeholder further information about the current Interim Order No. 3. As a result, the regulators have […]
MedMira Provides a Pre-Annual General Meeting Update

Halifax, Nova Scotia, 4 February, 2022 – Today, MedMira Inc. (MedMira) (TSXV: MIR) provides a pre-Annual General Meeting (AGM) update on its regulatory and product development progress. This includes its COVID-19 and its infectious disease products with the latest pre-submission for MedMira’s HCV Rapid Test to the FDA. This update serves the purpose to inform […]
MedMira’s COVID-19 Tests – for ANY STAGE

Download the MedMira COVID-19 testing overview
MedMira Announces VYRA™ CoV2Flu and Additional Regulatory Opportunities

Halifax, Nova Scotia, 21 December, 2021 – Today, MedMira Inc. (MedMira) (TSXV: MIR) announces the expansion of its VYRATMproduct line by launching its VYRA™ CoV2Flu Rapid Antigen Rapid Test (VYRA™ CoV2Flu). Based on MedMira’s proprietary technology, this 3-in-1 test is developed to distinguish between SARS-CoV-2 and Influenza A or B infections. Furthermore, the Company takes […]
Performance Update on World Health Organisation SARS-CoV2 Serology Standards

Halifax, Nova Scotia, 14 June, 2021 – MedMira Inc. (MedMira) (TSXV: MIR) announces the World Health Organization (WHO) SARS-CoV-2 serology standards testing results. The REVEALCOVID-19™ PLUS Total Antibody [PLUS] and the REVEALCOVID-19™ Nab-Y Competitive Neutralizing Antibody Test [Nab-Y] have achieved a 100% agreement. On March 29th, 2021, the WHO announced the first International Standards for […]
Product and Regulatory Update on MedMira’s COVID-19 Product Family

Halifax, Nova Scotia, 03 March, 2021 – MedMira Inc. (MedMira) (TSXV: MIR) announces the expansion of its product portfolio and outlines the company’s COVID-19 market and regulatory plan. MedMira has utilized its patented Rapid Vertical Flow™ (RVF™) technology and developed the company’s first rapid antigen test,VYRA CoV-2 Antigen Test (VYRA CoV-2), designed to detect SARS-CoV-2 […]
Progress Update on MedMira’s COVID-19 Product Family

Halifax, Nova Scotia, 29 January, 2021 – Today, MedMira Inc. (MedMira) (TSXV: MIR) announces the development of a rapid antibody test prototype that detects the presence of the neutralizing antibodies against the SARS-CoV-2 virus. These antibodies bind to the specific parts of the virus, decreasing the viral infectivity and potentially protecting the patient from the […]
MedMira Announces Product Update

Halifax, Nova Scotia, 30 December, 2020 – Today, MedMira Inc. (MedMira) (TSXV: MIR), is pleased to announce its validated REVEALCOVID-19™ PLUS Total Antibody Test for the detection of total antibodies against both the Nucleocapsid and Spike regions of the SARS-CoV-2. REVEALCOVID-19™ PLUS Total Antibody Test is an update to MedMira’s REVEALCOVID-19™ Total Antibody Test that […]
MedMira reports additional independent performance evaluation results of REVEALCOVID-19™

Halifax, Nova Scotia, 7th of October, 2020 – Today, MedMira Inc. (MedMira) (TSXV: MIR) announces the results of the latest independent performance evaluation results of REVEALCOVID-19TM Total Antibody Test. The study was carried out at a state licensed, state-of-the-art hospital in Texas (between June and September 2020). This facility utilizes a patient-centred model to provide […]
MedMira Announces Update on Development of Point-of-Care Antibody Test

Halifax, Nova Scotia, 15th of April, 2020 – MedMira Inc. (MedMira) (TSXV: MIR), announced today that it has completed the development of the serological Point-of-Care (POC) testing solution with immediate result. Based on MedMira’s unique and patented Rapid Vertical Flow™ (RVF) technology, the newly developed REVEALCOVID-19™ delivers immediate results without the need for any additional […]